Further in vitro and in vivo characterization confirms that selpercatinib is selective against RET alterations, including fusions and activating mutations, is well-tolerated upon daily oral administration, and elicited rapid clinical response in two patient cases (MTC and NSCLC) (265). This evidence concerns the gene RET and non-small cell lung carcinoma.